Chronic Spontaneous Urticaria (CSU) – Market Access and Reimbursement Insights Report – 2025
Chronic Spontaneous Urticaria (CSU) Market Access and Reimbursement Insights Thelansis’s “Chronic Spontaneous Urticaria (CSU) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Chronic Spontaneous Urticaria (CSU) Overview Chronic spontaneous urticaria, also known as chronic idiopathic urticaria, is defined as the presence of wheals, as well as possibly associated angioedema, for six weeks or longer in the absence of known triggering factors. The condition is known to last for a period of time, averaging five years, but can last longer in severe cases, especially if accompanied by angioedema. In addition, a great level o...